Team

Management

Michael McFadden, BBA

CEO and Director

Michael McFadden, BBA

CEO and Director

Mr. McFadden brings more than 30 years of successful leadership experience spanning pre-IND drug discovery through the commercialization and has launched over a dozen therapies in neurology, psychiatry, endocrinology and urology. He has over 16 years’ experience in Neuroscience. Previous leadership roles have included Chief Commercial Officer at MPower Health, Chief Commercial Officer at Urovant Sciences (Nasdaq: UROV), and SVP Sales and Marketing at Avanir Pharmaceuticals (Nasdaq: AVNR). Prior to these roles, Mr. McFadden held leadership roles at Amylin Pharmaceuticals (Nasdaq: AMLN) and Pharmacia. He serves on advisory boards at MPower Health and MindLab.

Don Kalkofen, BA

Chief Financial Officer

Don Kalkofen, BA

Chief Financial Officer

Mr. Kalkofen’s experience includes twenty years as a CFO in both public and private companies.  Prior to joining Alpha Cognition, Mr. Kalkofen most recently served as CFO of Protagonist Therapeutics Inc. (Nasdaq: PTGX), a publicly-traded biopharmaceutical company where he was instrumental in supporting the Company’s successful capital and debt financings, in excess of $550 million. Mr. Kalkofen’s has also held key management positions including the CFO of several financial services and global SAAS companies as well as supporting global medical device and specialty pharmaceutical companies in key financial areas. He started his career at PricewaterhouseCoopers, received his B.A. in accounting from Washington State University, and is a Certified Public Accountant and Certified Global Management Accountant.

Lauren D'Angelo, MBA

Chief Operating Officer

Lauren D'Angelo, MBA

Chief Operating Officer

Ms. D'Angelo brings more than 20 years experience leading successful drug commercialization efforts across 8 therapeutic areas, including multiple CNS therapies, six of which have become blockbuster brands. Specialty areas she has worked in include Central Nervous System, CV, Oncology, GI, Pain, Respiratory, Urology and Diabetes. She has extensive marketing, sales, and operations experience. She was recognized as a 2023 PharmaVoice Top 100 Industry Leader, Medical Marketing & Media's (MM+M) 2022 Woman of Distinction, MM+M's 2017 Woman to Watch, and was selected as one of Pharmaceutical Executive's Emerging Pharma Leaders for 2020.

Denis Kay, MSc, PhD

Chief Scientific Officer

Denis Kay, MSc, PhD

Chief Scientific Officer

Dr. Kay is the Co-founded the Company’s original company Neurodyn Life Sciences (NLS), in August 2006 and acted as NLS’s Chief Scientific Officer since that time. In 2017 he assumed the role of Chief Scientific Officer at ACI. He brings more than 30 years of experience in the development and characterization of animal models of neurological diseases, and 7 years of early-stage Central Nervous System clinical development experience in. He is a grant recipient of the Michael J. Fox Foundation and has received funding from numerous agencies for research and product development programs.

Directors

Len Mertz, BBA, MPA

Chairman

Len Mertz, BBA, MPA

Chairman

Mr. Mertz has been a director since Alpha Cognition's founding and was named Chairman in 2021. He is also the Chairman of Shannon West Texas Memorial Hospital, a CMS rated 5-star hospital, with currently budgeted gross revenues exceeding $1 billion. He has over 35 years of experience as a co-founder, board member, or investor in various companies including Triumvira Immunologics and Akido Labs. In addition, he serves on the board of the First National Bank of Mertzon and is a co-founder of Mayne & Mertz, Inc. an oil & gas exploration company. He began his career as a certified public accountant and obtained his BBA in Finance with Highest Honors and his Masters in Professional Accounting both from the University of Texas at Austin.

John Havens, BS

Director

John Havens, BS

Director

Since 1978, Mr. Havens has been the President of Seismic Exchange, Inc. Mr. Havens also has a long history as an entrepreneur as both a founder and significant investor in various industries, with a focus on growth through vertical integration and strategic acquisitions. He has served as Vice Chairman/Board Member of the Houston Astros and as an active member of numerous other business and community boards.

Phillip Mertz, AB

Director

Phillip Mertz, AB

Director

Mr. Mertz became a director in 2019. He is also the CEO of Subtle Technology, a neurotechnology company focused on non-invasive brain-machine interface solutions to neurodegenerative diseases and cognitive enhancement. In addition, he has over 15 years of investment experience, and is currently a partner in Mertz Holdings through which he invests in public and private companies. He is also a co-founder of Secure Open Solutions, a cybersecurity and compliance management company. Previously he led business development for CNG Energy and worked as a management consultant with Touchstone Consulting Group. He graduated from Harvard University in 2006 with an A.B. in Economics.

Rajeev "Rob" Bakshi, BBA

Director

Rajeev "Rob" Bakshi, BBA

Director

Mr. Bakshi is currently the CEO of Active Witness Corp, which develops disruptive technology for Access Control to make buildings and facilities safe. He previously was the co-founder of the technology company, Silent Witness Enterprises Ltd., which was listed on the TSX and NASDAQ. He oversaw the company's growth strategy before being sold to Honeywell. In 2009, Mr. Bakshi established Apivio Systems Inc and from 2013-2017 he served as CEO. Apivio Systems Inc was acquired by Nuri Telecom Company in the spring of 2017. Mr Bakshi is an accomplished real estate and technology investor, and advises both private and public companies.

Ken Cawkell, LLB

Director and Founder

Ken Cawkell, LLB

Director and Founder

Mr. Cawkell has been involved for over 25 years in the biotech industry as both a professional advisor, investor and as the founding principal of Alpha Cognition and its predecessor the Neurodyn Group. He is a member of the British Columbia Bar Association and in 1987, he co-founded the law firm Cawkell Brodie LLP. Mr. Cawkell has gained extensive strategic and development experience and has a history of value creation, as a result of his long-term association with numerous public and private companies. He has been involved in several successful exits and currently sits on the Board of TSE listed Well Health Technologies a leading integrated health care provider. He is a past member of the National Research Council of Canada IMB/INH Advisory Board and a number of biotech industry associations.

Michael McFadden, BBA

CEO and Director

Michael McFadden, BBA

CEO and Director

Mr. McFadden brings more than 30 years of successful leadership experience spanning pre-IND drug discovery through the commercialization and has launched over a dozen therapies in neurology, psychiatry, endocrinology and urology. He has over 16 years’ experience in Neuroscience. Previous leadership roles have included Chief Commercial Officer at MPower Health, Chief Commercial Officer at Urovant Sciences (Nasdaq: UROV), and SVP Sales and Marketing at Avanir Pharmaceuticals (Nasdaq: AVNR). Prior to these roles, Mr. McFadden held leadership roles at Amylin Pharmaceuticals (Nasdaq: AMLN) and Pharmacia. He serves on advisory boards at MPower Health and MindLab.

Corporate

Read More

Latest News

View All

TSX-V: ACI

15 min delay
Last$7.56
Change$-0.09
Open7.63
Vol400566
High7.65
Low7.49
Stock Information